SCL Science

SCL Science Equity

The The Equity of SCL Science (246960.KQ) as of Oct 16, 2026 is 24.45 B KRW. In the previous year, The Equity was 15.52 B KRW — a change of 57.56% (higher).

Equity

24.45 BKRW

YoY

57.56%

Last updated:

In 2025, SCL Science's equity was 24.45 B KRW, a 57.56% increase from the 15.52 B KRW equity in the previous year.

The SCL Science Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
9.52 B KRW
Jan 1, 2019
15.08 B KRW
Jan 1, 2020
12.94 B KRW
Jan 1, 2021
10.08 B KRW
Jan 1, 2022
13.05 B KRW
Jan 1, 2023
18.90 B KRW
Jan 1, 2024
15.52 B KRW
Jan 1, 2025
24.45 B KRW
The SCL Science Equity history
YEAREquityYoY
24.45 BKRW+57.56%
15.52 BKRW-17.91%
18.90 BKRW+44.90%
13.05 BKRW+29.43%
10.08 BKRW-22.13%
12.94 BKRW-14.19%
15.08 BKRW+58.46%
9.52 BKRW+207.38%
3.10 BKRW-49.02%
6.07 BKRW-186.94%
-6.99 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

SCL Science Stock analysis

What does SCL Science do? SCL Science Inc, listed on the Korean stock exchange with ticker 246960.KQ and ISIN KR7246960009, is a healthcare company headquartered in Seoul, South Korea. The company went public on February 1, 2019, as indicated by its IPO date. SCL Science Inc operates within the healthcare sector, focusing on the development and commercialization of medical products. According to the provided information, the company manufactures and sells hemostatic medical agents, which are used to control bleeding in medical procedures. The company's products include medical hemostats and sealants that utilize biomimetic technology, a technology inspired by natural biological processes. The company's website is innotherapy.com, which may provide further details about its products and services. SCL Science Inc is based in Seoul, South Korea, and its primary business activities are centered around the healthcare industry, specifically in the field of hemostatic solutions. The company's focus on biomimetic technology suggests an innovative approach to developing medical products that mimic natural biological mechanisms. The company's operations are likely aimed at providing medical professionals with effective tools for managing bleeding during surgical and other medical procedures. The company's market presence is within South Korea, though it may have international reach through its website and product distribution channels. The information provided does not include details on the company's revenue, market share, or specific competitors, nor does it mention any acquisitions or key personnel beyond the general description of its business activities. SCL Science is one of the most popular companies on Eulerpool.

Equity Details

Analyzing SCL Science's Equity

SCL Science's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding SCL Science's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating SCL Science's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

SCL Science's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in SCL Science’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about SCL Science stock

The Equity of SCL Science is 24.45 B KRW in 2025.

The Equity of SCL Science changed from 15.52 B KRW to 24.45 B KRW, representing a 57.56% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity SCL Science since 2006 – with annual values, charts, and detailed analysis.

The Equity's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's SCL Science historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — SCL Science

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — SCL Science